Post-Conference Perspectives: MOUNTAINEER Trials in GI Malignancies - Episode 5

Promising Early Data from GI Malignancy Trials

Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.

EP. 1: Recent Advancements and Current Areas of Focus in the Treatment of mCRC
EP. 2: HER2 as a Potential Drug Target and its Prevalence in GI Malignancies
EP. 3: Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC
EP. 4: MOUNTAINEER Trial: Rationale, Results and Clinical Implications
Now Viewing
EP. 5: Promising Early Data from GI Malignancy Trials

Related Content:

Post-Conference Perspectives: MOUNTAINEER Trials in GI MalignanciesOncLive News Network®Gastrointestinal Cancer
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
Dr Punekar on the Evaluation of NT-112 in KRAS G12D+ Advanced Solid Tumors
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups